The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bioverativ's Revenue for the
three
months ended in Dec. 2017 was $329 Mil. Bioverativ's average Accounts Receivable for the
three
months ended in Dec. 2017 was $194 Mil.
Hence, Bioverativ's Receivables Turnover for the
three
months ended in Dec. 2017 was 1.70.
Bioverativ Receivables Turnover Historical Data
The historical data trend for Bioverativ's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bioverativ's Receivables Turnover
For the Biotechnology subindustry, Bioverativ's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioverativ's Receivables Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioverativ's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bioverativ's Receivables Turnover falls into.
Bioverativ Receivables Turnover Calculation
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Bioverativ's Receivables Turnover for the fiscal year that ended in Dec. 2017 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bioverativ Receivables Turnover Related Terms
Thank you for viewing the detailed overview of Bioverativ's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIVV has been successfully added to your 